This site is for US healthcare professionals to provide online access to current, accurate, scientific information about our products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor for medical advice.

  1. Home
  2. Announcements
  3. Selected Announcement

SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide) Dear Healthcare Professional Letter, December 2020

A Dear Healthcare Professional Letter was issued for SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide) in December 2020.

Please view the full Prescribing Information, including BOXED WARNING, for SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide).

For product-related questions, please call our contact center at 1-800-Janssen (1-800-526-7736), or email your Medical Information Request and a response will be provided promptly.